A comparison of beclomethasone aqueous spray and aerosol delivery system in nasal polyps: A randomized control trial

Abstract

Background: Considering the effect of beclomethasone on allergic rhinitis or nasal polyps, it has been attempted to find the best method of using this drug to have the maximum effect and increase the patients' satisfaction. Therefore, the aim of this study was to compare the efficacy of beclomethasone aerosol and aqueous nasal sprays in the patients with nasal polyps. Materials and Methods: This double-blind randomized clinical trial was conducted on 60 patients with nasal polyps. The patients were divided into two groups. The first group (beclomethasone dipropionate aqueous BD-AQ group) was treated with daily two puffs of beclomethasone aqueous nasal spray 50 mu g in each nostril, and the second group (beclomethasone dipropionate aerosol BD-A group) was treated with two puffs of aerosol beclomethasone 50 mu g in each nostril daily for 6 months. At the beginning of the study, the sino-nasal outcome test-22 (SNOT-22) and Lund-Mackay scores were recorded after the evaluation of disease status and the severity of symptoms. Results: The results of this study demonstrated that the mean changes in Lund-Mackay and SNOT-22 scores (83 +/- 6.30 and 4.25 +/- 31.60, respectively) in the BD-A group were significantly higher than the BD-AQ group (2.01 +/- 3.87and 9.83 +/- 24.13, respectively) (P < 0.05), but there was no significant difference in the patients' satisfaction between the two groups (P > 0.05). Conclusion: According to the results of this study, patients with nasal polyps showed a significant improvement following both the interventions, but the disease severity in the BD-A group was significantly higher than the BD-AQ group based on the mean values of Lund-Mackay score.